ProJect Pharmaceutics and TUM-Spin-off ImevaX announce agreement on development of pharmaceutical formulation for IMX101
Munich/Martinsried, November, 2013 ProJect Pharmaceutics announces that it has signed a development agreement with ImevaX, a spin-off project from the research group of Prof. Dr. Markus Gerhard from the Technische Universität München, Institute for Medicinal Microbiology, Immunology and Hygiene, aimed at developing a formulation for a recombinant vaccine against Helicobacter pylori. IMX101 is a multicomponent […]